Czech Republic is a country rich in history considering it was only declared independent in 1993. Castles, Architecture, Music and Arts – an incredible country to experience. Famous for its beer, the country has much more to offer to anyone who visits.
Czechia has recently been trending as a dominant European clinical trial market. Contributing to this fact are the population exceeding 10 million, excellent ICH-GCP compliance, the presence of specialized, qualified and well-equipped clinical sites. All of that makes Czechia a very attractive region for clinical trials.
Among the pathologies with high incidence rate neoplasms, cardiovascular and digestive diseases, respiratory infections and mental disorders.
With over 250 hospitals (including major and university hospitals) and several hundreds clinics and other healthcare institutions, both public and private, Czechia demonstrates a very high density of potential clinical sites. The predominant part of health expenditure in the country is being financed by the public health insurance system.
Czech investigators are well educated, experienced in ICH GCP, and committed to delivering high quality clinical data.
Key local authority: Ministry of Health of Czech Republic